Abivax publishes 2025 financial calendar

Abivax publishes 2025 financial calendar paris, france – january 28, 2025 – 8:30 am cet – abivax sa (euronext paris: fr0012333284 – abvx / nasdaq: abvx) (“abivax” or the “company”), a clinical-stage biotechnology company developing innovative therapies to address chronic inflammatory diseases, today published its expected 2025 financial communications calendar. monday, march 24, 2025 (after us market closes) 2024 annual business and financial report (as of december 31, 2024) press release universal registration document (euronext) annual report on form 20-f monday, june 2, 2025 (after us market closes) 2025 q1 financial results (as of march 31, 2025) press release report on form 6-k friday, june 6, 2025         2025 annual general meeting (agm) live meeting in paris, france monday, august 11, 2025 (after us market closes) 2025 half-year business and financial report (as of june 30, 2025) press release half-year financial report (euronext) report on form 6-k monday, december 15, 2025 (after us market closes) 2025 q3 financial results (as of september 30, 2025) press release report on form 6-k about abivax abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
ABVX Ratings Summary
ABVX Quant Ranking